For many people living with HIV, the daily pill is more than a medicine. It is a small, daily reminder of the diagnosis, and sometimes something to hide when a date stays over. New findings presented this week at the HIV Drug Therapy Glasgow 2026 congress (November 8 to 11) suggest that an investigational once-weekly pill may ease some of that weight, at least for people already doing well on treatment.

The data come from ISLEND-2, a phase 3 trial of a weekly tablet that combines two drugs, islatravir (from Merck) and lenacapavir (from Gilead). The regimen is still investigational and is not approved by the FDA.

What the study looked at

ISLEND-2 enrolled adults whose HIV was already suppressed on daily oral treatment. According to aidsmap's report from the congress, 314 people were randomly assigned to switch to the weekly pill and 312 continued their usual daily regimen. The trial was open-label, so participants and their clinicians knew which treatment they were taking. Most people (88%) were already on a single daily tablet, so for many the change was from one pill a day to one pill a week.

Two posters looked at how people felt about the switch:

• A questionnaire analysis of quality of life and treatment preference after one year (poster P057, Ramgopal and colleagues).
• An interview substudy with 20 participants and 10 health care providers (poster P056, Orkin and colleagues).

What participants reported after one year

As reported by aidsmap, comparisons between the two groups favored the weekly pill:

• Preference: 72% of people in the weekly group strongly preferred it to their previous daily regimen.
• Satisfaction: about 68% of the weekly group said they were "very satisfied," compared with 46% of those who stayed on daily treatment.
• Burden: 82% of the weekly group said their regimen was not at all burdensome, compared with 61% of the daily group.
• Reminders of HIV: about 16% of the weekly group said their medication reminded them of their HIV status "very much" or "quite a bit," compared with 25% of the daily group.
• Taking doses on time: 86% of the weekly group said they took their pill on the advised day and time all of the time, compared with 75% of the daily group.

Worries about medication, and worries about other people finding out their HIV status, also changed more favorably in the weekly group. There was no difference between the groups in how people rated their overall health. The trial's main results, reported earlier, found that the weekly pill worked as well as daily treatment at week 48 in keeping HIV suppressed (non-inferior, in trial terms).

"Normal is the perfect word"

In the interviews, one participant described the daily pill as a constant reminder of having a condition, and said that one pill a week now felt like taking an ordinary painkiller: "So, normal is the perfect word."

According to the interview substudy poster, most of the 20 interviewees said the switch had a positive effect on their quality of life. Themes included fewer daily reminders of living with HIV, relief from pill fatigue, easier travel and, for a few people, improved privacy. The health care providers interviewed said the weekly pill would be easy to use in clinical practice and could help people take treatment as planned.

Why it matters for dating and relationships

Treatment schedules are not just a medical detail. People living with HIV often talk about the small moments that a daily pill creates: a pill bottle in an overnight bag, a dose to take at a partner's place before you have disclosed, or a trip where you worry about the routine. A weekly option could make some of those moments less frequent. That is one reason these quality-of-life findings got attention.

It is also worth repeating what has not changed. Any regimen that keeps your viral load undetectable means you cannot pass HIV to a partner through sex. That is the science behind U=U (Undetectable = Untransmittable), and it is the same whether a person takes a pill every day, a pill every week, or an injection every few months. If you are curious about long-acting options that already exist, read our coverage of real-world results for long-acting HIV shots.

Whether and when to share your status is your choice, and the rules about disclosure vary by state. For practical ideas on the conversation, see how life with HIV has changed in 35 years and what comes next after a partner accepts your disclosure. Couples where one partner has HIV and the other does not can find more in our guide to serodiscordant relationships.

Important caveats

• Open-label design: people knew they were switching to a new weekly pill, so expectations may have shaped how they answered.
• A small, specific interview group: the 20 interviewees were mostly men (18 of 20), aged 39 to 71, and 15 of them already preferred less frequent treatment before the switch.
• Trial support: participants may have had support inside the study that is not always available in everyday care.
• Not yet approved: the weekly islatravir and lenacapavir pill is investigational. Merck's November 2 announcement describes it as an investigational regimen still under study.

The bottom line

For people already undetectable on daily pills, early evidence suggests a weekly pill could feel less like a daily reminder of HIV, with most trial participants preferring it. It is not available yet, and today's daily pills and long-acting shots remain effective choices. If your current routine feels like a burden, that is worth raising with your HIV care provider, who can talk through the options that fit your health and your life.

Looking for people who already get it? Explore HIV dating on MeetPositives or read more about finding love and connection while living with HIV.

Sources

• aidsmap. "'Normal is the perfect word': participants describe switching to weekly HIV treatment." HIV Glasgow 2026 coverage, November 10, 2026.
• Ramgopal M, et al. "Quality of life and treatment preference with weekly ISL/LEN versus standard of care: Week 48 patient-reported outcome analysis of the Phase 3 ISLEND-2 Study." Poster P057, HIV Glasgow 2026.
• Orkin C, et al. "Understanding treatment experiences with weekly oral islatravir/lenacapavir in the Phase 3 ISLEND-2 study: Participant and provider interviews." Poster P056, HIV Glasgow 2026.
• Merck. "Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026." News release, November 2, 2026.

This article is for general information only and is not medical or legal advice. It does not create a doctor-patient relationship. Talk with a licensed health care provider about your own situation. Laws vary by state; for legal questions, talk with a licensed attorney. This article does not recommend or promote any product.